Back to results

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Primary Purpose

Acute Myeloid Leukemia, Multiple Myeloma

Status

Terminated

Phase

Phase 1

Locations

International

Study Type

Interventional

Intervention

MLM-CAR44.1 T-cells at day 0 Single intravenous infusion

About this trial

This is an interventional treatment trial for Acute Myeloid Leukemia

Eligibility Criteria

1 Year - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients must meet all the following inclusion criteria to be eligible for the study.

Written informed consent before any study-related procedure.
Adults and children:
1. Adults 18 to 75 (65) years old with AML or MM.
2. Children 1 to 17 years old with AML, only in Phase IIa.
Confirmed diagnosis of AML or MM as follows:
1. AML: Primary or secondary AML (any subtype except acute promyelocytic leukemia) according to World Health Organization (WHO) classification.
2. MM with measurable disease as defined by the International Myeloma Working Group (IMWG).
Patients with relapse or refractory disease:
1. AML patients must be unlikely to benefit from cytotoxic chemotherapy as follows:
  - Leukemia refractory to at least 2 induction attempts.
  - Leukemia in relapse within 1 year following complete response (CR) after at least 2 induction attempts.
  - High-risk leukemia in adults according to 2017 European LeukemiaNet (ELN) in first relapse after a hypomethylating agent or a cycle containing cytarabine at a dose ≥ 1g/sqm a day (e.g. FLAG-IDA), except for FLT3-mutated AML.
  - High-risk leukemia in children as defined by the Italian Association of Pediatric Hematology and Oncology (AIEOP).
2. Patients with MM must have a relapse or refractory disease after at least 4 different prior treatments in 3 treatment lines, or 4 treatments in 2 treatment lines in case of early relapsing patients (relapse in less than 1.5 years). Treatments include:
  - Proteasome inhibitor
  - High-dose alkylating agent if patients less than 70 years old
  - Immunomodulatory drug (IMID)
  - A monoclonal antibody (i.e. anti CD38 monoclonal antibody)
Positive CD44v6 expression on tumor cells by flow cytometry.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Life expectancy of at least 12 weeks.
Adequate organ function (hepatic, cardiac, pulmonary).
Recovery from toxicities of clinical consequence attributed to previous chemotherapy to CTCAE v5.0 Grade 1 (i.e., certain toxicities such as alopecia will not be considered in this category).
Ability to comply with study procedures, including hospitalization and protocol-specified acquisition of blood and/or bone marrow specimens.
Willing to be followed up long term, i.e. a 15-year follow up as required by health authorities for cell and gene therapy products.
Women of childbearing potential must test negative for pregnancy at enrolment and during the study.

Exclusion Criteria:

At screening: patients must meet none of the following exclusion criteria to be eligible for the study:

History of or candidate for allogeneic stem cell transplantation.
Cardiovascular, pulmonary, renal, and hepatic functions that in the judgment of the investigator are insufficient for the patient to undergo investigational CAR T-cell therapy.
Any history of or suspected current autoimmune disorders (apart from vitiligo, resolved childhood atopic dermatitis, Graves' disease clinically controlled).
History of rheumatologic disorders requiring specific treatment at any time in the patient's medical history.

Sites / Locations

Department of Haematooncology, Fakultni Nemocnice
IRCCS San Raffaele
IRCCS Ospedale Pediatrico Bambino Gesù

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

MLM-CAR44.1 T-cells infusion

Arm Description

PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design. PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD). Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3

Outcomes

Primary Outcome Measures

Phase I: Maximum Tolerated Dose (MTD) and the Recommended Phase IIa Dose of MLM-CAR44.1 T-cells in AML and MM

MTD established through BOIN design and the dose-limiting toxicities (DLTs) occurring following CAR T-cell infusion.

Phase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells

Safety will be evaluated by analyzing the type, frequency and severity of adverse events (AE) and by monitoring for systemic reactions (fever, tachycardia, nausea and vomiting, joint pain, skin rash). Overall, 3 study emergent serious adverse events (SAEs) were reported in patients treated with MLM-CAR44.1 T-cells.

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens: 3 months post-infusion will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required.

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 12 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 24 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in AML.

The hematologic disease response will be classified according to ELN criteria.

Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM

The hematologic disease response will be classified according to IMWG criteria

Secondary Outcome Measures

Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in AML

The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM

Hematologic disease response evaluated at Day 28 following CART-cell infusion, as overall response rate (ORR), stringent complete response (sCR), CR, very good partial response (VGPR) and partial response (PR).

Phase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples

The levels will be evaluated by flow cytometry and qPCR (in vivo pharmacokinetic profile).

Phase I: The Percentage of Patients for Whom Activation of Suicide Gene Was Needed

Suicide gene activation and elimination of transduced cells will be established through administration of ganciclovir in case of cytokine-release syndrome (CRS) and other MLM-CAR44.1 T-cell related toxicities.

Phase IIa: Hematologic Disease Response in AML

The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

Phase IIa: Hematologic Disease Response in MM

The hematologic disease response will be defined based on the overall response rate (ORR): stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to IMWG criteria

Phase IIa: Overall Survival (OS)

Overall Survival (OS) is defined as the time from the date of MLM-CAR44.1 T-cell infusion to the date of last follow-up or death due to any cause, whichever occurs first. One patients out of the 2 treated was still alive at the date of the early study termination. One patient died after EURE-CART-1 cell infusion, at day 121, for disease progression.

Full Information

NCT ID

NCT04097301

First Posted

August 5, 2019

Last Updated

December 20, 2021

Sponsor

AGC Biologics S.p.A.

Collaborators

Horizon 2020 - European Commission

1. Study Identification

Unique Protocol Identification Number

NCT04097301

Brief Title

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Official Title

A Phase I-IIa Trial to Assess the Safety and Antitumor Activity of Autologous CD44v6 CAR T-cells in Acute Myeloid Leukemia and Multiple Myeloma Expressing CD44v6

Study Type

Interventional

2. Study Status

Record Verification Date

December 2021

Overall Recruitment Status

Terminated

Why Stopped

Inability to close the study in a clinically relevant time frame

Study Start Date

August 27, 2019 (Actual)

Primary Completion Date

June 18, 2021 (Actual)

Study Completion Date

June 18, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

AGC Biologics S.p.A.

Collaborators

Horizon 2020 - European Commission

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).

Detailed Description

The study is a seamless Phase I/IIa, open-label, multicenter clinical trial that combines Phase I dose escalation based on toxicity with Phase IIa dose expansion based on antitumor activity. Considering the "first in human" nature of this clinical study, the Bayesian Optimal Interval Design (BOIN) has been chosen to minimize any risks of exposure to the novel CD44v6 CAR T-cells during dose escalation. The study population is made up of patients with relapsed/refractory AML or MM expressing CD44v6. The medicinal product under investigation (MLM-CAR44.1 T-cells) is patient specific as it is prepared starting from lymphocytes of the patient collected through lymphocyte apheresis. These autologous T-cells are expanded in vitro in large numbers and genetically modified to express the CAR CD44v6ΔNL gene and thus acquire antitumor functions. As a safety feature, the MLM-CAR44.1 T-cells are genetically modified to also express the HSV-TK Mut2 gene (suicide gene), which can be selectively activated in case of severe toxicity through the administration of ganciclovir (GCV), leading to the death of proliferating CAR T-cells. The aim of this study is to assess the safety, antitumor activity and feasibility of CD44v6 CAR T cell immunotherapy in AML and MM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Acute Myeloid Leukemia, Multiple Myeloma

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1, Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

8 (Actual)

8. Arms, Groups, and Interventions

Arm Title

MLM-CAR44.1 T-cells infusion

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

MLM-CAR44.1 T-cells at day 0 Single intravenous infusion

Other Intervention Name(s)

CAR-T cells

Intervention Description

Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.

Primary Outcome Measure Information:

Title

Phase I: Maximum Tolerated Dose (MTD) and the Recommended Phase IIa Dose of MLM-CAR44.1 T-cells in AML and MM

Description

MTD established through BOIN design and the dose-limiting toxicities (DLTs) occurring following CAR T-cell infusion.

Time Frame

Within 30 days following CAR T-cell infusion, assessed as day 0

Title

Phase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells

Description

Time Frame

For 30 days following CAR T-cell infusion, assessed as day 0.

Title

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion

Description

Time Frame

3 months after infusion (assessed as day 0)

Title

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion

Description

Time Frame

6 months after infusion (assessed as day 0)

Title

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 12 Months Post-infusion

Description

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

Time Frame

12 months after infusion (assessed as day 0)

Title

Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 24 Months Post-infusion

Description

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

Time Frame

24 months after infusion (assessed as day 0)

Title

Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in AML.

Description

The hematologic disease response will be classified according to ELN criteria.

Time Frame

2 months after MLM-CAR44.1 T-cell infusion, assessed as day 0

Title

Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM

Description

The hematologic disease response will be classified according to IMWG criteria

Time Frame

3 months after T-cell infusion, assessed as day 0

Secondary Outcome Measure Information:

Title

Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in AML

Description

The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

Time Frame

1 and 2 months following T-cell infusion, assessed as day 0

Title

Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM

Description

Time Frame

1 and 3 months following T-cell infusion, assessed as day 0

Title

Phase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples

Description

The levels will be evaluated by flow cytometry and qPCR (in vivo pharmacokinetic profile).

Time Frame

At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0

Title

Phase I: The Percentage of Patients for Whom Activation of Suicide Gene Was Needed

Description

Time Frame

At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0

Title

Phase IIa: Hematologic Disease Response in AML

Description

The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

Time Frame

1, 2 and 6 months after MLM-CAR44.1 T-cell infusion, assessed as day 0.

Title

Phase IIa: Hematologic Disease Response in MM

Description

Time Frame

1, 2 and 6 months after T-cell infusion, assessed as day 0

Title

Phase IIa: Overall Survival (OS)

Description

Time Frame

At the date of the early study termination

Other Pre-specified Outcome Measures:

Title

Exploratory Outcome of Phase IIa: Percentages of Patients With Minimal Residual Disease

Description

AML: proportion of patients with a molecular complete response (CR); MM: proportion of patients with a molecular CR.

Time Frame

AML: 2 months after infusion, assessed as day 0. MM: 3 months after infusion, assessed as day 0

10. Eligibility

Sex

All

Minimum Age & Unit of Time

1 Year

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Patients must meet all the following inclusion criteria to be eligible for the study. Written informed consent before any study-related procedure. Adults and children: Adults 18 to 75 (65) years old with AML or MM. Children 1 to 17 years old with AML, only in Phase IIa. Confirmed diagnosis of AML or MM as follows: AML: Primary or secondary AML (any subtype except acute promyelocytic leukemia) according to World Health Organization (WHO) classification. MM with measurable disease as defined by the International Myeloma Working Group (IMWG). Patients with relapse or refractory disease: AML patients must be unlikely to benefit from cytotoxic chemotherapy as follows: Leukemia refractory to at least 2 induction attempts. Leukemia in relapse within 1 year following complete response (CR) after at least 2 induction attempts. High-risk leukemia in adults according to 2017 European LeukemiaNet (ELN) in first relapse after a hypomethylating agent or a cycle containing cytarabine at a dose ≥ 1g/sqm a day (e.g. FLAG-IDA), except for FLT3-mutated AML. High-risk leukemia in children as defined by the Italian Association of Pediatric Hematology and Oncology (AIEOP). Patients with MM must have a relapse or refractory disease after at least 4 different prior treatments in 3 treatment lines, or 4 treatments in 2 treatment lines in case of early relapsing patients (relapse in less than 1.5 years). Treatments include: Proteasome inhibitor High-dose alkylating agent if patients less than 70 years old Immunomodulatory drug (IMID) A monoclonal antibody (i.e. anti CD38 monoclonal antibody) Positive CD44v6 expression on tumor cells by flow cytometry. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Life expectancy of at least 12 weeks. Adequate organ function (hepatic, cardiac, pulmonary). Recovery from toxicities of clinical consequence attributed to previous chemotherapy to CTCAE v5.0 Grade 1 (i.e., certain toxicities such as alopecia will not be considered in this category). Ability to comply with study procedures, including hospitalization and protocol-specified acquisition of blood and/or bone marrow specimens. Willing to be followed up long term, i.e. a 15-year follow up as required by health authorities for cell and gene therapy products. Women of childbearing potential must test negative for pregnancy at enrolment and during the study. Exclusion Criteria: At screening: patients must meet none of the following exclusion criteria to be eligible for the study: History of or candidate for allogeneic stem cell transplantation. Cardiovascular, pulmonary, renal, and hepatic functions that in the judgment of the investigator are insufficient for the patient to undergo investigational CAR T-cell therapy. Any history of or suspected current autoimmune disorders (apart from vitiligo, resolved childhood atopic dermatitis, Graves' disease clinically controlled). History of rheumatologic disorders requiring specific treatment at any time in the patient's medical history.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Fabio Ciceri, MD

Organizational Affiliation

IRCCS San Raffaele

Official's Role

Principal Investigator

Facility Information:

Facility Name

Department of Haematooncology, Fakultni Nemocnice

City

Ostrava

State/Province

Czech Republic

Country

Czechia

Facility Name

IRCCS San Raffaele

City

Milan

Country

Italy

Facility Name

IRCCS Ospedale Pediatrico Bambino Gesù

City

Roma

Country

Italy

12. IPD Sharing Statement

Citations:

PubMed Identifier

33554732

Citation

Stornaiuolo A, Valentinis B, Sirini C, Scavullo C, Asperti C, Zhou D, Martinez De La Torre Y, Corna S, Casucci M, Porcellini S, Traversari C. Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer. Hum Gene Ther. 2021 Jul;32(13-14):744-760. doi: 10.1089/hum.2020.216. Epub 2021 May 5.

Results Reference

derived

Learn more about this trial

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

We'll reach out to this number within 24 hrs